Pharsight

Xywav patents expiration

XYWAV's oppositions filed in EPO
XYWAV IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8731963 JAZZ Sensitive drug distribution system and method
Dec, 2022

(1 year, 5 months ago)

US8731963

(Pediatric)

JAZZ Sensitive drug distribution system and method
Jun, 2023

(11 months ago)

US9132107 JAZZ Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
Jan, 2033

(8 years from now)

US10675258 JAZZ Method of using gamma-hydroxybutyrate compositions for the treatment of disorders
Jan, 2033

(8 years from now)

US8901173 JAZZ Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
Jan, 2033

(8 years from now)

US10195168 JAZZ Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders
Jan, 2033

(8 years from now)

US8591922 JAZZ Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
Jan, 2033

(8 years from now)

US11554102 JAZZ Gamma-hydroxybutyrate compositions and their uses for the treatment of disorders
Jan, 2033

(8 years from now)

US10864181 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US11253494 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US9050302 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US10213400 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US9486426 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US8772306 JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Mar, 2033

(8 years from now)

US9486426

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(9 years from now)

US8772306

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(9 years from now)

US11253494

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(9 years from now)

US10864181

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(9 years from now)

US9050302

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(9 years from now)

US10213400

(Pediatric)

JAZZ Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
Sep, 2033

(9 years from now)

US11426373 JAZZ Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
Sep, 2037

(13 years from now)

Xywav is owned by Jazz.

Xywav contains Calcium Oxybate; Magnesium Oxybate; Potassium Oxybate; Sodium Oxybate.

Xywav has a total of 21 drug patents out of which 2 drug patents have expired.

Expired drug patents of Xywav are:

  • US8731963
  • US8731963*PED

Xywav was authorised for market use on 21 July, 2020.

Xywav is available in solution;oral dosage forms.

Xywav can be used as method of treating a patient with a prescription drug using a computer database in a computer system for distribution, method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with a salt of gamma-hydroxybutyrate when divalproex sodium is concomitantly administered, method of treating patients with a salt of gamma-hydroxybutyrate when divalproex sodium is concomitantly administered, method of treating excessive daytime sleepiness and/or cataplexy in narcolepsy patients with sodium oxybate when divalproex sodium is concomitantly administered., method of reducing adverse effects in patients suffering from excessive daytime sleepiness and/or cataplexy in narcolepsy who are concomitantly administered sodium oxybate and divalproex sodium, treatment of cataplexy or excessive daytime sleepiness (eds) in patients 7 years of age and older with narcolepsy with a mixture of sodium, potassium, magnesium, and calcium salts of ghb, treatment of cataplexy or excessive daytime sleepiness (eds) in patients 7 years of age and older with narcolepsy with a mixture of sodium, potassium, magnesium, and calcium salts of ghb administered between 2 and 4 hours after eating.

The generics of Xywav are possible to be released after 19 September, 2037.

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-361) Jul 21, 2027
New Indication(I-870) Aug 12, 2024
Orphan Drug Exclusivity(ODE-369) Aug 12, 2028
Orphan Drug Exclusivity(ODE-231) Jul 21, 2027
New Product(NP) Jul 21, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE ingredient

Market Authorisation Date: 21 July, 2020

Treatment: Method of treating a patient with a prescription drug using a computer database in a computer system for distribution; Treatment of cataplexy or excessive daytime sleepiness (eds) in patients 7 years ...

Dosage: SOLUTION;ORAL

How can I launch a generic of XYWAV before it's drug patent expiration?
More Information on Dosage

XYWAV family patents

Family Patents